Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urologic Neoplasms 2Stomach Neoplasms 2Brain Neoplasms 2beta-Thalassemia 1Urinary Bladder Neoplasms 1Supratentorial Brain Tumor Surgery 1Strabismus 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Complications 1Post-operative Residual Curarization 1Obesity 1Neuromuscular Blockade 1Neoplasms 1Myasthenia Gravis 1Hepatoblastoma 1Endobronchial Metastases 1Emergence Delirium 1Delayed Emergence from Anesthesia 1

Interventions

Cyclophosphamide 6Granulocyte Colony-Stimulating Factor 5Melphalan 4Etoposide 4Cisplatin 4Carboplatin 4sodium thiosulfate 3fludarabine 3Thiotepa 3Mesna 3Filgrastim 3Busulfan 3pembrolizumab 2Vorinostat 2Vincristine 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Ifosfamide 2Gemcitabine 2Fluorouracil 2Doxorubicin 2talazoparib 1sintilimab 1sargramostim 1pegylated granulocyte colony-stimulating factor 1omburtamab I-131 1lenvatinib 1irinotecan sucrosofate 1fludarabine phosphate 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hepatoblastoma × Sugammadex × Clear all
NCT03728543 2018-11-02

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Neoplasms, beta-Thalassemia, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡